108.Konig P, Poehler J, Barbero G. A placebo-controlled, double blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis.// Pediatr Pulmonol 1998; 25:32 - 36
109.Hordvik NL, Sammut PH, Judy CG, et al. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis.// Am J Respir Crit Care Med 1996; 154:156 - 160
110.Zach MS, Oberwaldner B, Forche G, et al. Bronchodilators increase airway instability in cystic fibrosis.// Am Rev Respir Dis 1985; 131:537 - 543
111.Salvatore D, D’Andria M. Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis.//Pediatr Pulmonol 2002; 34:11 - 15
112.Hordvik NL, Sammut PH, Judy CG, et al. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis.// Pediatr Pulmonol 2002; 34:287 - 296
113.Weintraub SJ, Eschenbacher WL. The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with // CF. Chest 1989; 95:861 - 864
114.Aмелина Е.Л., Черняк А.В. - Эффективность тиотропия бромида у больных муковисцидозом. // Сборник тезисов 15-го Национального конгресса по болезням органов дыхания. Москва, 29 ноября-2 декабря 2005 г. Пульмонология. Приложение. 2005. 49 (160).
115.Stafanger G, Koch C. N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility. // Eur Respir J 1989; 2:234 - 237
116.Ratjen F, Wonne R, Posselt HG, et al. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. // Eur J Pediatr 1985; 144:374 - 378
117.Ranasinha C, Assoufi B, Shak S et al Effecacy and safety of short-term administration of aerosolised recombinant human DNase in adult whit stable stage cystic fibrosis. // Lancet. - 1993. - V.342. - P.199-202.
118.Shah PL, Bush A, Canny GJ et al. Recombinant human Dnase 1 (rhDNase) in cystic fibrosis patients whit severe pulmonary disease: short-term, double-blind stady followed by a six month open-label triatment. // Eur Respir J. - 1995. - V.8. - P.954-958.
119.Amelina E., Cherniak A., Voznesenskiy N., Cherniaev A., Chuchalin A. - The effect of daily inhaled DNAse in adult patients with cystic fibrosis. The Netherlands J. of Medicine. 1999. 54; suppl. s81 (228).
120.Shah PL, Convey SP, Scott SF, Rainisio M, Wildman M, Stableforth D, Hodson ME. A case-controlled stady with Dornase Alfa to evaluate impact on disease progression over a 4-year period. // Respiration. - 2001. - P.68
121.Hodson M E, Shah P L. Dnase trials in cystic fibrosis. // Eur Resp J. - 1995. - V.8. - P.1786-1791
122.D Desmond KJ, Schwenk WF, Thomas E, et al. Immediate and long-term effects of chest physiotherapy in patients with cystic fibrosis. J Pediatr 1983; 103:538 - 542
123.Reisman JJ, Rivington-Law B, Corey M, et al. Role of conventional physiotherapy in cystic fibrosis. // J Pediatr 1988; 113:632 - 636
124.MMcIlwaine PM, Wong LT, Peacock D, et al. Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. // J Pediatr 1997; 131:570 - 574
125.McIlwaine PM, Wong LT, Peacock D, et al. Long-term comparative trial of positive expiratory pressure versus oscillating positive expiratory pressure (flutter) physiotherapy in the treatment of cystic fibrosis. // J Pediatr 2001; 138:845 - 850
126. Enright S, Chatham K, Ionescu AA, Unnithan VB, Shale DJ.2004;126(2):405-11 Inspiratory muscle training improves lung function and exercise capacity in adults with cystic fibrosis. // Chest. 2004;126(2):405-11
127.de, van Aalderen WM, Kraan J, Koeter GH, van der Schans CP ., Inspiratory muscle training in patients with cystic fibrosis. // Respir Med. 2001 ;95(1):31-6.
128.
129.Meyer KC, Lewandoski JR, Zimmerman JJ et al. Human neutrophyl elastase elastase/alpha1-antiprotease complex in cystic fibrosis - comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy.// Am Rev Respir Dis 1991;144(3): 580-585
130.PedersenSS, Hoiby N. Et al. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.// Acta Paediat Scand. 1997; 76:955-961.
131.Marks MI, Antibiotic therapy of bronchopulmonary infections in cystic fibrosis: the American approach. // Antibiotic Chemother 1989; 42: 229-236.
132.Esmond G, Butler M, McCormack A, et al. Comparison of hospital and home intravenous antibiotic therapy in adults with cystic fibrosis. // J Cystic Fibrosis 2002;1(Suppl 1):P362.
133. Pond M, Newport M, Joanes D, et al. Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis. / Eur Respir J 1995;7:1640 - 4.
134.Thornton, R Elliott, M P Tully, M Dodd and A K Webb;Long term clinical outcome of home and hospital intravenous antibiotic treatment in adults with cystic fibrosis // Thorax 2004;59:242-246
135.Amelina E., Senkevich N., Cherniak A., Cherniaev A., Chuchalin A. - Home intravenous therapy in adult cystic fibrosis patients. The impact on lung function and quality of life. Abstracts World Congress on Lung Health and 10th ERS Annual Congress. Florence, Italy, August 30-September 3, 2000. // Eur.Respir.J. 2000. 16; suppl.31. 123s (P915).
136.Marco T, Asensio O, Bosque M, et al. Home intravenous antibiotics for cystic fibrosis (Cochrane Review). Issue 1. In: The Cochrane Library. Oxford, Update Software, 2001
137.Сенкевич Н.Ю, Амелина Е.Л. Качество жизни взрослых больных муковисцидозом: факты и гипотезы. // Пульмонология - 1999 - N3- С.51-57
138.Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis.// N Engl J Med 1999; 340:23 - 30
139.Nickerson B, Montgomery A, Kylstra J, et al. Safety and effectiveness of 2 years of treatment with intermittent inhaled tobramycin in CF patients [abstract].// Pediatr Pulmonol 1999; Suppl 19:243 - 244
140.Авдеев С.Н., Самойленко В.А., Амелина Е.Л., Чучалин А.Г. Интенсивная терапия при муковисцидозе у взрослых. //. Пульмология, 2000: 3; 87-99)
141.SpectorM., Stern R. Pneumothorax in cystic fibrosis: a 26-year experience. // Ann. Thorac. Surg. 1989; 47: 204-207.
142.Sweeney., Fellows K. Bronchial artery embolization for severe haemoptysis in cystic fibrosis.// Chest 1990; 97:1322-1326.
143.Hodson M.E., Madden B.P.,Steven M.H.et al. Non-invasive mechanical ventilation for cystic fibrosis-a potential bridge to transplanttion. // Eur. respir. J. 1991; 4:524-527.
144.. Johnson LG, Knowles MR: New therapeutic strategies for cystic fibrosis lung disease. Cystic Fibrosis in Adults. Philadelphia: Lippincott-Raven, 1999, 233-258
document:
$pr:
version: 01-2007.1
codepage: windows-1251
type: klinrek
id: kli2049549
: 08.5. БРОНХОЭКТАЗЫ
meta:
author:
fio[ru]: Я.Н. Шойхет, Н.М. Лепихин, Д.Н. Лепихина
codes:
next:
type: dklinrek
code: III.III
type: dkli00181
ОПРЕДЕЛЕНИЕ
Бронхоэктазы (БЭ) - стойкое, необратимое расширение ветвей бронхиального дерева, обусловленное деструкцией стенок бронхов и/или нарушением нервно-мышечного тонуса вследствие воспаления, склероза, дистрофии, гипоплазии их структурных элементов.
Впервые БЭ были описаны Р.Т.Г. Лаэннеком в 1819 г. Проблеме их генеза, диагностики и лечения за последние 50 лет посвящено много работ [1 - 3, 7 - 10, 12, 13].
Бронхоэктатическая болезнь (бронхоэктазии) - гнойно-воспалительный процесс в резко расширенных деформированных бронхах с инфильтративными и склеротическими изменениями в перибронхиальном пространстве, ведущий к дальнейшему необратимому расширению бронхов с нарушением их дренажной функции, к развитию ателектазов, эмфиземы, цирроза в регионарной зоне паренхимы легкого.
